AC is better than EDI for LC visibility

Article

If the goal is to improve lamina cribrosa (LC) visibility, adaptive compensation (AC) is better than enhanced depth imaging (EDI), according to new research.

If the goal is to improve lamina cribrosa (LC) visibility, adaptive compensation (AC) is better than enhanced depth imaging (EDI), according to new research published in Investigative Ophthalmology and Visual Science. Visibility of the posterior LC remains poor, so it is probably not realistic to use LC thickness as a glaucoma biomarker.

The researchers, from Singapore, French Polynesia and London, compared LC visibility in optic disc images obtained from 60 patients with glaucoma and 60 patients serving as controls. They used three optical coherence tomography (OCT) devices, with and without EDI and AC: They obtained a horizontal B-scan through the centre of the disc using two spectral-domain OCT devices (Spectralis, Heidelberg Engineering; Cirrus, Carl Zeiss Meditec - both with and without EDI) and a swept-source OCT device (DRI, Topcon). The investigators applied AC after they obtained the scans, to improve image quality.

Four masked observers evaluated LC visibility by grading the 1,200 images in random order. They graded the anterior LC on a 0-to-4 scale, the LC insertions on a scale of 0 to 2, and the posterior LC either as 0 or 1. The observers used generalized estimating equations to evaluate the effect on LC visibility of EDI, AC, glaucoma severity and other clinical and demographic factors.

The observers found that anterior LC was the most detectable feature, then LC insertions. “AC improved anterior LC visibility independent of EDI,” they wrote. “Cirrus+EDI+AC generated the greatest anterior LC visibility grades.”

Regarding LC insertions visibility, they said, “DRI+AC was the best method. Visibility of the posterior LC was consistently poor. Neither glaucoma severity nor clinical/demographic factors consistently affected LC visibility.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.